Skip to main content

Home Activities Product Pipeline
Print Bookmark

Product Pipeline

The Company is currently developing a range of pharmaceutical product projects that are mostly based on its Multi Matrix MMX® technology. This technology allows the delivery of active pharmaceutical ingredients mainly into the lumen of the colon through tablet erosion in a delayed and controlled manner. This has the effect that the active pharmaceutical ingredients can be applied to the full length of the colon.

The Company's proprietary clinical development pipeline specifically addresses innovative treatments for Inflammatory Bowel Diseases, with the group's lead product Lialda® launched in the US and EU, and with the nutraceutical Zacol NMX® launched for the local market in Italy and in selected Eastern European countries. In addition, one product has completed Phase III and has been filed for registration, one product is in Phase III, two are in Phase II, one is in phase Phase I and 3 products are in preclinical phase. The Company has one new chemical entity, an anti androgen directed at topical skin diseases such as acne, hirsutism and alopecia that is in Phase II. 

Cosmo has developed and is working on the following compound pharmaceutical products and nutraceuticals:

Graph displaying compound pharmaceutical products against Inflammatory Bowel Disease as well as nutraceuticals developed by Cosmo Link to CB-03-01 page Link to CB-03-01 page Link to CB-01-16 page Link to CB-17-01 page Link to Heparin page Link to Rifamycin page Link to Budesonide page Link to Zacol page Link to Lialda and Mesavant page